Enzo Biochem Current Ratio 2006-2021 | ENZ

Enzo Biochem current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Enzo Biochem Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-07-31 $0.07B $0.03B 2.71
2021-04-30 $0.07B $0.03B 2.44
2021-01-31 $0.07B $0.03B 2.33
2020-10-31 $0.07B $0.03B 2.09
2020-07-31 $0.07B $0.03B 2.10
2020-04-30 $0.07B $0.03B 2.27
2020-01-31 $0.07B $0.02B 3.07
2019-10-31 $0.08B $0.02B 3.36
2019-07-31 $0.08B $0.02B 5.09
2019-04-30 $0.09B $0.02B 5.61
2019-01-31 $0.06B $0.02B 3.84
2018-10-31 $0.08B $0.02B 4.15
2018-07-31 $0.08B $0.02B 4.12
2018-04-30 $0.09B $0.02B 4.63
2018-01-31 $0.09B $0.02B 4.51
2017-10-31 $0.09B $0.02B 4.66
2017-07-31 $0.09B $0.02B 5.00
2017-04-30 $0.09B $0.02B 5.16
2017-01-31 $0.09B $0.02B 4.95
2016-10-31 $0.09B $0.02B 4.35
2016-07-31 $0.09B $0.02B 4.44
2016-04-30 $0.06B $0.02B 2.55
2016-01-31 $0.06B $0.03B 2.41
2015-10-31 $0.05B $0.03B 2.05
2015-07-31 $0.05B $0.02B 1.94
2015-04-30 $0.04B $0.02B 1.60
2015-01-31 $0.04B $0.02B 1.63
2014-10-31 $0.04B $0.03B 1.62
2014-07-31 $0.04B $0.03B 1.63
2014-04-30 $0.04B $0.02B 1.73
2014-01-31 $0.03B $0.02B 1.35
2013-10-31 $0.03B $0.02B 1.34
2013-07-31 $0.03B $0.02B 1.37
2013-04-30 $0.03B $0.02B 1.46
2013-01-31 $0.03B $0.02B 1.67
2012-10-31 $0.04B $0.02B 1.93
2012-07-31 $0.04B $0.02B 2.13
2012-04-30 $0.04B $0.02B 2.50
2012-01-31 $0.04B $0.02B 2.56
2011-10-31 $0.05B $0.02B 2.71
2011-07-31 $0.05B $0.02B 2.90
2011-04-30 $0.05B $0.02B 3.35
2011-01-31 $0.05B $0.02B 3.22
2010-10-31 $0.06B $0.02B 3.66
2010-07-31 $0.06B $0.02B 3.71
2010-04-30 $0.06B $0.01B 4.78
2010-01-31 $0.07B $0.02B 3.54
2009-10-31 $0.07B $0.01B 5.47
2009-07-31 $0.07B $0.01B 5.34
2009-04-30 $0.08B $0.02B 5.05
2009-01-31 $0.09B $0.01B 6.54
2008-10-31 $0.10B $0.01B 7.72
2008-07-31 $0.11B $0.01B 7.95
2008-04-30 $0.12B $0.01B 10.49
2008-01-31 $0.12B $0.01B 11.37
2007-10-31 $0.13B $0.01B 9.59
2007-07-31 $0.13B $0.01B 8.88
2007-04-30 $0.14B $0.01B 15.58
2007-01-31 $0.13B $0.01B 16.04
2006-10-31 $0.09B $0.01B 11.02
2006-07-31 $0.09B $0.01B 14.50
2006-04-30 $0.09B $0.01B 13.52
2006-01-31 $0.10B $0.01B 18.42
2005-10-31 $0.10B $0.01B 16.60
2005-07-31 $0.10B $0.01B 13.36
2005-04-30 $0.10B $0.01B 19.19
2005-01-31 $0.11B $0.01B 16.01
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.161B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00